Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
0.7300
-0.0229 (-3.04%)
Mar 31, 2025, 2:15 PM EDT - Market open
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -65.93% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 9.43, with a low estimate of 3.00 and a high estimate of 14. The average target predicts an increase of 1,191.78% from the current stock price of 0.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +995.89% | Mar 21, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +584.93% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $13 | Strong Buy | Maintains | $18 → $13 | +1,680.82% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +2,297.26% | Dec 10, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +1,543.84% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
n/a
from 258.19M
Revenue Next Year
n/a
EPS This Year
-0.99
from -1.70
EPS Next Year
-1.04
from -0.99
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 102.2M | ||
| Avg | n/a | n/a | 41.3M | ||
| Low | n/a | n/a | 7.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | -0.56 | -0.48 | ||
| Avg | -0.99 | -1.04 | -1.00 | ||
| Low | -1.39 | -1.59 | -1.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.